Abstract
Background
Idiopathic hyposmia (IH) is a prodromal marker of Parkinson disease (PD). However, IH is common in the general population and only a minority will develop PD. Identification of individuals with IH at prodromal stage of PD would serve to select them to implement neuroprotective agents, when available.
Objective
To identify prodromal PD in IH patients using the Movement Disorders Society (MDS) research criteria for prodromal PD.
Methods
We applied the MDS research criteria for prodromal PD to 25 consecutive patients older than 50 years who were self-referred for smell loss and had IH, and to 18 controls. A number of risk and prodromal PD markers were assessed in all participants including REM sleep behavior disorder (RBD) by video-polysomnography and nigrostriatal dopaminergic dysfunction by DAT-SPECT. After follow-up of 4.7 ± 2.2 years, participants were re-assessed to look for incident PD.
Results
Prodromal PD probability was higher in patients than in controls (19.45 ± 34.9% versus 1.74 ± 4.48%; p = 0.019). Four (16%) patients met the criteria of prodromal PD surpassing 80% probability (99.8%, 99.5%, 88.3%, 86.4%). Three (12%) patients had RBD and four (16%) abnormal DAT-SPECT. At the end of follow-up, one (4%) IH patient who had RBD and baseline prodromal PD probability of 86.4% developed PD, while all controls remained disease free.
Conclusions
Prodromal PD is infrequent among IH patients. MDS research criteria for prodromal PD are useful to identify a subgroup of IH patients at high risk of PD when RBD is assessed by video-polysomnography and nigrostriatal dopamine deficiency with DAT-SPECT.
Similar content being viewed by others
Availability of data and material
The data that support the findings of this study are available by request to the corresponding author.
References
de Lau LM, Breteler MM (2006) Epidemiology of Parkinson’s disease. Lancet Neurol 5:525–535
de Lau LM, Giesbergen PC, de Rijk MC, Hofman A, Koudstaal PJ, Breteler MM (2004) Incidence of parkinsonism and Parkinson disease in a general study: The Rotterdam Study. Neurology 63:1204–1244
Postuma RB, Berg D, Stern M, Poewe W, Marek K, Litvan I (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30:1591–1599
Mahlknecht P, Seppi K, Poewe W (2015) The concept of prodromal Parkinson’s disease. J Parkinsons Dis 5:681–697
Noyce AJ, Lees AJ, Schrag AE (2016) The prediagnostic phase of Parkinson’s disease. J Neurol Neurosurg Psychiatry 87:871–878
Postuma RB, Berg D (2016) Advances in markers of prodromal Parkinson disease. Nat Rev Neurol 12:622–634
Ward CD, Hess WA, Calne DB (1983) Olfactory impairment in Parkinson’s disease. Neurology 33:943–946
Hawkes C (2003) Olfaction in neurodegenerative disorder. Mov Disord 18:364–372
Tissingh G, Berendese HW, Bergmans P et al (2011) Loss of olfaction in de novo and treated Parkinson’s disease: possible implications for early diagnosis. Mov Disord 16:41–46
Pont-Sunyer C, Hotter A, Gaig C et al (2015) The onset of nonmotor symptoms in Parkinson’s disease (The ONSET PD Study). Mov Disord Mov Disord 30:229–237
Marin C, Vilas D, Langdon C et al (2018) Olfactory dysfunction in neurodegenerative diseases. Curr Allergy Asthma Rep 18(8):42
Vilas D, Tolosa E, Quintana M et al (2020) Olfaction in LRRK2 linked Parkinson’s disease: is it different from idiopathic Parkinson’s disease? J Parkinsons Dis. https://doi.org/10.3233/JPD-201972
Haehner A, Hummel T, Hummel C, Sommer U, Junghanns S, Reichmann H (2007) Olfactory loss may be a first sign of idiopathic Parkinson’s disease. Mov Disord 22:839–842
Ross GW, Petrovitch H, Abbott RD et al (2008) Association of olfactory dysfunction with risk for future Parkinson’s disease. Ann Neurol 67:167–173
Jennings D, Siderowf A, Stern M et al (2017) Conversion to Parkinson disease in the PARS hyposmic and dopamine transporter-deficit prodromal cohort. JAMA Neurol 74:933–940
Noyce AJ, R’Bibo L, Peress L et al (2017) PREDICT-PD: an online approach to prospectively identify risk indicators of Parkinson’s disease. Mov Disord 32:219–226
Postuma RB, Gagnon J-F, Vendette M, Desjardins C, Montplaisir JY (2011) Olfaction and color vision identify impending neurodegeneration in rapid eye movement sleep behavior disorder. Ann Neurol 69:811–818
Mahlknecht P, Iranzo A, Högl B et al (2015) Olfactory dysfunction predicts early transition to a Lewy body disease in idiopathic RBD. Neurology 84:654–658
Ponsen MM, Stoffers D, Booji J, van Eck-Smit BLF, Wolters E, Berendse HW (2004) Idiopathic hyposmia as a preclinical sign of Parkinson’s disease. Ann Neurol 56:173–181
Murphy C, Schubert CR, Cruickshanks KJ, Klein BEK, Klein R, Nondhal DM (2002) Prevalence of olfactory impairment in older adults. JAMA 288:2307–2312
Mullol J, Alobid I, Mariño-Sánchez F et al (2012) Furthering the understanding of olfaction, prevalence of loss of smell and risk factors: a population-based survey (OLFACAT study). BMJ Open 2:e001256
Siderowf A, Jennings D, Eberly S et al (2012) Impaired olfaction and other prodromal features in the parkinson at-risk syndrome study. Mov Disord 27:406–412
Haehner A, Masala C, Walter S, Reichmann H, Hummel T (2019) Incidence of Parkinson’s disease in a large patient cohort with idiopathic smell and taste loss. J Neurol 266:339–345
Berg D, Postuma RB, Adler CH et al (2015) MDS research criteria for prodromal Parkinson’s disease. Mov Disord 30:1600–1609
Heinzel S, Berg D, Gasser T et al (2019) Update of the MDS research criteria for prodromal Parkinson’s disease. Mov Disord 34:1464–1470
Mahlknecht P, Gasperi A, Djamshidian A et al (2018) Performance of the Movement Disorders Society criteria for prodromal Parkinson’s disease: a population-based 10-year study. Mov Disord 33:405–413
Pilotto A, Heinzel S, Suenkel U et al (2017) Application of the movement disorder society prodromal Parkinson’s disease research criteria in 2 independent prospective cohorts. Mov Disord 32:1025–1034
Iranzo A, Stefani A, Serradell M et al (2017) Characterization of patients with longstanding idiopathic REM sleep behavior disorder. Neurology 89:242–248
Fereshtehnejad SM, Montplaisir JY, Pelletier A, Gagnon JF, Berg D, Postuma RB (2017) Validation of the MDS research criteria for prodromal Parkinson’s disease: longitudinal assessment in a REM sleep behavior disorder (RBD) cohort. Mov Disord 32:865–873
Skorvanek M, Ladomirjakova Z, Han V et al (2017) Prevalence of prodromal Parkinson’s disease as defined by MDS research criteria among elderly patients undergoing colonoscopy. J Parkinsons Dis 7:481–489
Mirelman A, Saunders-Pullman R, Alcalay RN et al (2018) Application of the Movement Disorder Society prodromal criteria in healthy G2019S-LRRK2 carriers. Mov Disord 33:966–973
Cardesin A, Alobid I, Benitez P et al (2006) Barcelona Smell Test-24 (BAST-24): validation and smell characteristics in the healthy Spanish population. Rhinology 44:83–89
American Academy of Sleep Medicine (2014) International classification of sleep disorders, 3rd edn. American Academy of Sleep Medicine, Darien
Frauscher B, Iranzo A, Gaig C et al (2012) Normative EMG values during REM sleep for the diagnosis of REM sleep behavior disorder. Sleep 35:835–847
Iranzo A, Santamaría J, Valldeoriola F et al (2017) Dopamine transporter imaging deficit predicts early transition to synucleinopathy in idiopathic rapid eye movement sleep behavior disorder. Ann Neurol 82:419–428
Goetz CG, Tilley BC, Shaftman SR et al (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 23:2129–2170
Freeman R, Wieling W, Axelrod FB et al (2011) Consensus statement on the definition of orthostatic hypotension, neutrally mediated syncope and the postural tachycardia syndrome. Clin Auton Res 21:69–72
Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC (2006) Functional bowel disorders. Gastroenterology 130:1480–1491
Johns MW (1991) A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14:540–545
Nasreddine ZS, Phillips NA, Bedirian V et al (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53:695–699
Delgado C, Araneda A, Behrens MI (2019) Validation of the Spanish-language version of the Montreal Cognitive Assessment test in adults older than 60 years. Neurologia 34(6):376–385
American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders, 5th edn. Arlington, Washington
Doty RL (1995) The smell identification test administration manual, 3rd edn. Sensonics, Philadelphia
Mahlknecht P, Gasperi A, Willeit P et al (2016) Prodromal Parkinson’s disease as defined per MDS research criteria in the general elderly community. Mov Disord 31:1405–1408
Iranzo A, Santamaria J, Tolosa E (2016) Idiopathic rapid eye movement sleep behaviour disorder: diagnosis, management, and the need for neuroprotective interventions. Lancet Neurol 15:405–419
Pujol M, Pujol J, Alonso T et al (2017) Idiopathic REM sleep behavior disorder in the elderly Spanish community: a primary care center study with a two-stage design using video-polysomnography. Sleep Med 40:116–121
Iranzo A, Fernández-Arcos A, Tolosa E et al (2014) Neurodegenerative disorder risk in Idiopathic REM sleep behavior disorder: study in 174 patients. PLoS One 9(2):e89741
Weil RS, Morris HR (2019) REM sleep behaviour disorder: an early window for prevention in neurodegeneration? Brain 142:498–501
Fantini ML, Postuma RB, Montplaisir J, Ferini-Strambi L (2006) Olfactory deficit in idiopathic rapid eye movements sleep behavior disorder. Brain Res Bull 70:386–390
Iranzo A, Serradell M, Vilaseca I et al (2013) Longitudinal assessment of olfactory function in idiopathic REM sleep behavior disorder. Parkinsonism Relat Disord 19:600–604
Jennings D, Siderowf A, Stern M et al (2014) Imaging prodromal Parkinson disease: the Parkinson Associated Risk Syndrome Study. Neurology 83:1739–1746
Filippi L, Manni C, Pierantozzi M et al (2005) 123I-FP-CIT semi-quantitative SPECT detects preclinical bilateral dopaminergic deficit in early Parkinson’s disease with unilateral symptoms. Nucl Med Commun 26:421–426
Booji J, Tissingh G, Boer GJ et al (1997) [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson’s disease. J Neurol Neurosurg Psychiatry 62:133–140
Fearnley JM, Lees AJ (1991) Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain 114:2283–2301
Benamer HTS, Patterson J, Wyper DJ, Hadley DM, Macphee GJ, Grosset DG (2000) Correlation of Parkinson’s disease severity and duration with [123I]-FP-CIT SPECT striatal uptake. Mov Disord 15:692–698
Iranzo A, Valldeoriola F, Lomeña F et al (2011) Progressive nigrostriatal dopaminergic dysfunction in idiopathic REM sleep behavior disorder: a prospective study. Lancet Neurol 10:797–805
Erro R, Picillo M, Vitale C et al (2013) Non-motor symptoms in early Parkinson’s disease: a 2-year follow-up study on previously untreated patients. J Neurol Neurosurg Psychiatry 84:14–17
Khoo TK, Yarnall AJ, Duncan GW et al (2013) The spectrum of nonmotor symptoms in early Parkinson disease. Neurology 80:276–281
Barone P, Antonini A, Colosimo C et al (2009) The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord 24:1641–1649
Gaenslen A, Swid I, Liepelt-Scarfone I, Godau J, Berg D (2011) The patients’ perception of prodromal symptoms before the initial diagnosis of Parkinson’s disease. Mov Disord 26:653–658
Schrag A, Horsfall L, Walters K, Noyce A, Petersen I (2015) Prediagnostic presentations of Parkinson’s disease in primary care: a case-control study. Lancet Neurol 14:57–64
Funding
This study was not funded.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
The authors had no financial disclosures and no conflict of interests concerning the research related to the current study.
Ethical standards
This human study has been approved by our local ethics committee and has therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
Ethics approval
The study was approved by the local ethics committee of our institution and written informed consent was obtained from all participants.
Rights and permissions
About this article
Cite this article
Marrero-González, P., Iranzo, A., Bedoya, D. et al. Prodromal Parkinson disease in patients with idiopathic hyposmia. J Neurol 267, 3673–3682 (2020). https://doi.org/10.1007/s00415-020-10048-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-020-10048-6